Transcript of "Global Life Sciences Trends and Opportunities 2012-2015"
Global Life Sciences Trends and Opportunities 2012–2015 Global Team Identifies Highlights Across Pharmaceutical/Biotechnology, Diagnostics, and Research IndustriesNB98November 2012
Why You Need to Know the Big PictureAs a pharma/biotech, in vitro diagnostic, or life science research industry leader,have you ever asked yourself the following questions: o How do changes in the pharmaceutical industry trickle down to the diagnostics and life sciences industries? o Which segments across pharma/biotech, diagnostics, and life sciences will be the highest growth markets by 2015? o Which companies are successful in the pharma/biotech, diagnostics, and life sciences markets and why? Does success in one market translate to success in another? o Is it the right time for your company to enter another life sciences market or segment? What are the prime opportunities and what are the risks? o Which non-traditional companies are entering life sciences markets? o What is impeding the growth of an „emerging‟ market? o What are the defining trends in the healthcare markets for 2012 and how this will change in 2015?NB98 2
What you will find in this deliverableAbstract:The new Frost & Sullivan research deliverable titled “Global Life Sciences Trends andOpportunities 2012-2015” analyzes critical trends and opportunities for 2012-2015 in thepharmaceutical/biotechnology, diagnostics, and life sciences research industries. It sources30+ Frost & Sullivan proprietary research deliverables across the United States, Europe,Brazil, Russia, Indonesia, Vietnam, and Sub-Saharan Africa representing over 100 primaryinterviews with industry leaders, key opinion leaders (KOLs) and end users. Exampleanalyses include growth areas now and developing, companies to watch, and a 2015 outlookfor global healthcare.Topics Covered:• Daunting Challenges for the Pharmaceutical Industry• Pharma‟s New Growth Strategies• Curbing the Costs of Drug Development (Pharmaceutical Outsourcing)• Lean Laboratories-Doing More With Less• Novel Biomarker Discovery Leading to Novel Therapeutics• Genetic Technologies are Integral to Healthcare• The Last Word-4 Major Predictions for the Industry NB98 3
Life Science Growth Areas: Now and Developing Can you afford to miss the ‘next big thing’? Recommended Growth Areas Now (2012) Future Markets With Strong Potential (2015)• Biologics are an industry innovation that continues to grow due • Biosimilars and biobetters will mature in the United to their high degree of efficacy. States.• Indications with high unmet need like complex disease and orphan disease are key opportunities. • Targeted therapies and companion diagnostics• Pharmaceutical outsourcing of clinical trials, manufacturing, will grow in disease other than cancer and and biosimilars development will continue to curb unsustainable infectious disease like diabetes and cholesterol costs of making drugs. control (e.g., statins).• Targeted therapies and companion diagnostics are prevalent in the treatment of cancer and some infectious diseases. • MicroRNA therapeutics will emerge as a result of• Generic pharmaceuticals in emerging markets improve access field advancement in microRNA tools and to healthcare within growing economies. microRNA as biomarkers.• Modern healthcare is rapidly adopting molecular diagnostics and will soon adopt next generation sequencing. • Affordable healthcare (generics and point-of-care-• Advanced tools enable single-cell analysis in R&D and testing) will usher in next wave emerging markets diagnostics. like Indonesia and Vietnam.• MicroRNA and epigenetics in disease fuel growth in tools and diagnostic tests.• Affordable, “personal,” low-throughput instruments are well matched to R&D budgets and improve access. Source: Frost & Sullivan analysis. NB98 4
Defining Healthcare Trends in the Future How will your company meet the future needs of the industry?Topic Present (2012) Future Outlook (2015)Clinical trial Clinical trials for new drugs center on Clinical trials will have more requirements like more effectiverequirements basic requirements such as treatment of the disease itself rather than just symptoms in comparison with placebo. addition to comparison with placebo. This trend is driven by demands from payers for reimbursement.Price of Biologics are expensive therapies with Increasing pressure on the soaring costs of biologics will beBiologics little competition. effective in stabilizing the rate of price increase.Miniaturization Nanotechnology and microfluidics Laboratories will be equipped with stripped-down, lower enable a miniaturization trend in R&D throughput, “personal” instruments that have advantages like a and diagnostics. smaller footprint and smaller price tags.Providers of Advanced fields like next generation There will be even greater consolidation of advanced testing,Advanced sequencing, oncology, and genomic regardless of technology, as there is no strong need to have itTechnologies analysis are becoming more at the regional level. centralized.Big Data in Genomic researchers are facing Genomic researchers will address more and more big dataGenomic interpretation issues of genomic issues like storage and database management.Research databases and differentiating what is or is not clinically useful.Personal Genomic analysis is conducted and Physicians may aggregate individual patient case data toGenomic Data performed primarily for the individual leverage daily practice findings in a sample population. This patients‟ needs. may be particularly useful in rare indications. Source: Frost & Sullivan analysis. NB98 5